Thermo Fisher reels in $7.2 billion deal, lands big share of biotech market

18 May 2017
mergers-acquisitions-big

Angling for a greater haul in the bullish market for biotech products, diversified medtech firm Thermo Fisher Scientific (NYSE: TMO) is to buy Netherlands-incorporated Patheon (NYSE: PTHN), a contract manufacturing organization.

Thermo Fisher will commence a tender offer to buy up shares in the company, which provides comprehensive biopharmaceutical development services, for around $7.2 billion, including $2 billion of net debt.

Patheon has developed into one of the world’s largest CMOs through a series of mergers and acquisitions, including a $2.65 billion deal with the pharmaceutical products business of Royal DSM (Euronext: DSM KON) in 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology